1CM
ADMA icon

1492 Capital Management’s ADMA Biologics ADMA Stock Holding History

1492 Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-113,155
Closed -$1.02M – 134
2026
Q1 		$1.02M Sell
113,155
-56,915
-33% -$898K 0.39% 73
2025
Q4 		$3.1M Sell
170,070
-1,112
-0.6% -$18.7K 1.19% 35
2025
Q3 		$2.51M Buy
171,182
+75,379
+79% +$1.29M 1.02% 40
2025
Q2 		$1.74M Buy
95,803
+46,717
+95% +$953K 0.8% 50
2025
Q1 		$974K Buy
+49,086
New +$849K 0.52% 56

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

1492 Capital Management's ADMA Position: Q2 2026 in Review

1492 Capital Management sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 113,155 shares — an estimated $1.02M sold.

1492 Capital Management first reported a position in ADMA in Q1 2025 and held it in 5 quarters. The position peaked at $3.1M in Q4 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • 1492 Capital Management reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • 1492 Capital Management sold 113,155 ADMA Biologics shares in Q2 2026, an estimated $1.02M.
  • 1492 Capital Management first reported a position in ADMA Biologics in Q1 2025 and held it in 5 quarters.
  • 1492 Capital Management's ADMA Biologics position peaked at $3.1M in Q4 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on 1492 Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.